The primary objective of this study was to identify the risk of metastasis to lymph nodes above the inferior mesenteric artery (IMA) in endometrioid-type endometrial cancer (EC) and the factors that influence metastasis. The study included patients who had been operated on for endometrioid-type EC in three gynecological oncology centers between 2007 and 2023. The supramesenteric lymph node (SM-LN) is the region between the left renal vein and the IMA, whereas the inframesenteric lymph node (IM-LN) is the region between the IMA and the aortic bifurcation, as determined by the level of the IMA. The study sample comprised 412 patients. The median number of lymph nodes excised per patient was 58. The median count was 37 for pelvic lymph nodes, 21 for para-aortic lymph nodes, 8 for IM-LN, and 13 for SM-LN. In the univariate analysis, the factors that were found to be statistically significant in determining SM-LN metastasis included tumor size, depth of myometrial invasion, uterine serosal invasion, lymphovascular space invasion (LVSI), cervical invasion, peritoneal cytology, adnexal metastasis, omental metastasis, non-nodal extrauterine metastasis, pelvic lymph node metastasis, and IM-LN metastasis. In the multivariate analysis, SM-LN metastasis was independently associated with tumor size, LVSI, pelvic lymph node metastasis, and IM-LN metastasis. In conclusion, in cases of intermediate-high risk EC, it is important to know that the disease spreads to SM-LN in 7.3% of patients. The efficacy of postoperative adjuvant treatment may be inadequate due to a lack of information regarding the SM-LN region.
22 July 2025 in SN Comprehensive Clinical Medicine
Background: Sentinel lymph node (SLN) mapping has become an established alternative to systematic lymphadenectomy for surgical staging in endometrial cancer. This study evaluated SLN mapping rates, anatomical distribution, factors associated with mapping failure, and perioperative outcomes in patients with early-stage endometrial cancer. Methods: This retrospective cohort study included patients with early-stage endometrial cancer who underwent SLN mapping during minimally invasive surgical staging between September 2022 and January 2025. Overall and bilateral SLN detection rates were calculated. Anatomical distribution of SLNs, factors associated with mapping failure (including a hemipelvis-level generalized estimating equation [GEE] analysis), and perioperative outcomes according to surgical approach were analyzed. Results: A total of 165 patients were included. The overall SLN detection rate was 96.4%, and bilateral mapping was achieved in 125 patients (75.8%). A total of 584 SLNs were removed, most commonly from the iliac basin. In the hemipelvis-level GEE analysis (330 hemipelves, 46 failures), ICG use (adjusted odds ratio [OR] 4.50, 95% confidence interval [CI] 1.07–18.83) and, in a sensitivity model, conventional laparoscopy compared with robotic surgery (OR 2.31, 95% CI 1.14–4.69) were associated with higher odds of mapping failure, whereas age and BMI were not. Operative time and intraoperative complication rates were comparable among laparoscopic, robotic-assisted, and vaginal natural orifice transluminal endoscopic surgery (vNOTES) procedures. Postoperative complication rates and length of hospital stay differed significantly across surgical approaches (both p = 0.002); post hoc pairwise comparison of complication rates showed that the difference was driven mainly by conventional laparoscopy compared with robotic-assisted surgery, whereas the small vNOTES group (n = 8) did not differ significantly from either approach and does not permit conclusions on its comparative safety. Conclusions: SLN mapping demonstrated high overall detection rates and acceptable bilateral mapping success in early-stage endometrial cancer. These findings support the feasibility of SLN mapping as a minimally invasive staging strategy in routine clinical practice.
Background: Serous epithelial ovarian cancer is typically diagnosed at an advanced stage and often recurs following treatment. Isolated organ recurrence is rare in this disease, making treatment planning a critical decision. Therefore, we investigated the survival rates of patients who developed isolated liver recurrence. Methods: The entire cohort included patients who underwent cytoreductive surgery between January 1993 and December 2020. We evaluated patients who completed primary chemotherapy after cytoreductive surgery based on their status of isolated liver recurrence. We created two groups: patients with isolated parenchymal recurrence and patients with isolated capsular recurrence. Staging was based on the International Federation of Gynecology and Obstetrics (FIGO) 2014 staging criteria. For patients treated before 2014, cancer staging was adapted to the FIGO 2014 system based on a surgical and pathological assessment. Results: The mean ages of patients with liver capsule and parenchymal recurrence at the time of primary surgery were 47 ± 10.6 and 49 ± 8.9 years, respectively. The median recurrence of patients with capsular recurrence was 13 (2–70) months. In patients with parenchymal recurrence, the duration was 10 months (4–80) and was statistically insignificant. While survival was 41.5 (5–120) months in patients with capsular recurrence, it was 34 (12–120) months in patients with parenchymal recurrence, but there was no statistical difference. Conclusions: In our 27 years’ of experience with EOC management, we have studied patients with isolated liver recurrences. The finding that either capsular or parenchymal liver recurrence has no significant impact on overall survival suggests that both types of recurrence can be managed with similar treatment and follow-up approaches. This observation could simplify patient management and improve outcomes by allowing clinicians to focus on optimal surgical and systemic treatment strategies rather than the anatomic pattern of recurrence.